LUNG - צמיחת הכנסות ב-12 חודשים נגררים Pulmonx Corporation

Stringent FDA requirements and patent protection create significant barriers to entry in the emphysema treatment segment. Pulmonx Corporation (LUNG) shows sales growth over the 12-month period compared to last year, driven by its leadership in COPD therapy with the Zephyr system. Effective cost management and sales scaling have solidified this trend, and the metric currently stands at -3.20.
Pulmonx Corp (LUNG) - פילוחי מדדים ודוחות פיננסיים

This indicator measures the percentage change in revenue over the last twelve months relative to the same period last year. By analyzing the rolling 12-month sales growth rate year-over-year on the GURU.Markets platform, an investor assesses the effectiveness of commercial expansion. The current value of -3.20 reflects the adoption dynamics of endobronchial valves in pulmonology centers. Scaling procedures with low variable costs for polymers ensures accelerated revenue. The positive trend confirms the fundamental resilience of the Pulmonx Corporation (LUNG) business model.